Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednisolone

FDA-approved product (tablet, oral), marketed as Cortalone, Delta-Cortef, Fernisolone-P and 4 more.

Registered studies
39
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Prednisolone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Contact dermatitis
  • Crohn's disease
  • Dermatitis herpetiformis
  • Dermatomyositis
  • Eosinophilic pneumonia
  • Epicondylitis
  • Erythema multiforme
  • and 42 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednisolone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednisolone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

    NCT03392909 · start 2018-07-05

    Registered record
    Registry ID
    NCT03392909
    Conditions
    Recessive Dystrophic Epidermolysis Bullosa
    Interventions
    Gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2018-07-05
    Completion
    2023-12-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecessive Dystrophic Epidermolysis Bullosa
    InterventionGentamicin
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Gentamicin for Junctional Epidermolysis Bullosa

    NCT03526159 · start 2018-06-01

    Registered record
    Registry ID
    NCT03526159
    Conditions
    Junctional Epidermolysis Bullosa
    Interventions
    Gentamicin Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2018-06-01
    Completion
    2020-08-31
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJunctional Epidermolysis Bullosa
    InterventionGentamicin Sulfate
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Efficacy of Topical Gentamycin for Hereditary Hypotrichosis Simplex Caused by Nonsense Mutations in CDSN

    NCT03492866 · start 2018-04

    Registered record
    Registry ID
    NCT03492866
    Conditions
    Hereditary Hypotrichosis Simplex
    Interventions
    Gentamicin Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04
    Completion
    2019-04
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Hypotrichosis Simplex
    InterventionGentamicin Sulfate
    PhasePhase 2
    Registry statusUnknown

  • New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

    NCT03294395 · start 2017-09-18

    Registered record
    Registry ID
    NCT03294395
    Conditions
    Gonorrhea
    Interventions
    Ertapenem 1000 MG; Fosfomycin Oral Suspension; Gentamicin Sulfate, Injectable; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-18
    Completion
    2020-06-05
    Enrolment
    346

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea
    InterventionErtapenem 1000 MG; Fosfomycin Oral Suspension; Gentamicin Sulfate, Injectable; Ceftriaxone
    PhasePhase 3
    Registry statusCompleted

  • Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy

    NCT03213249 · start 2017-07-25

    Registered record
    Registry ID
    NCT03213249
    Conditions
    Breast Implant Infection; Mammoplasty
    Interventions
    Normal saline; Cefazolin; Skin biopsy; Bilateral skin- or nipple-sparing mastectomies; Tissue expander; Breast implant; Autologous flap; Acellular dermal matrix sling; Gentamicin; Bacitracin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-07-25
    Completion
    2018-09-26
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Implant Infection; Mammoplasty
    InterventionNormal saline; Cefazolin; Skin biopsy; Bilateral skin- or nipple-sparing mastectomies +6 more
    PhasePhase 1
    Registry statusCompleted

  • INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI

    NCT03299387 · start 2017-06-28

    Registered record
    Registry ID
    NCT03299387
    Conditions
    Urinary Tract Infections
    Interventions
    Nitrofurantoin; Gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-06-28
    Completion
    2018-07-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionNitrofurantoin; Gentamicin
    PhasePhase 4
    Registry statusWithdrawn

  • Gentamicin for RDEB

    NCT03012191 · start 2017-02-02

    Registered record
    Registry ID
    NCT03012191
    Conditions
    Recessive Dystrophic Epidermolysis Bullosa
    Interventions
    Gentamicin Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-02-02
    Completion
    2018-08-31
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecessive Dystrophic Epidermolysis Bullosa
    InterventionGentamicin Sulfate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Retrospective Simplex High Viscosity (HV) Bone Cement Study

    NCT05659329 · start 2016-04-25

    Registered record
    Registry ID
    NCT05659329
    Conditions
    Arthritis Knee; Aseptic Loosening
    Interventions
    Simplex HV/Gentamicin Simplex HV bone cement
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04-25
    Completion
    2022-09-27
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis Knee; Aseptic Loosening
    InterventionSimplex HV/Gentamicin Simplex HV bone cement
    PhaseNot recorded
    Registry statusCompleted

  • Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

    NCT02698735 · start 2016-02-25

    Registered record
    Registry ID
    NCT02698735
    Conditions
    Recessive Dystrophic Epidermolysis Bullosa
    Interventions
    Gentamicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-02-25
    Completion
    2017-06-30
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecessive Dystrophic Epidermolysis Bullosa
    InterventionGentamicin; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

    NCT02447172 · start 2015-06

    Registered record
    Registry ID
    NCT02447172
    Conditions
    Foot Ulcer, Diabetic; Infection
    Interventions
    Gentamicin Collagen sponge; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-09
    Enrolment
    524

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFoot Ulcer, Diabetic; Infection
    InterventionGentamicin Collagen sponge; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

    NCT02427802 · start 2015-05

    Registered record
    Registry ID
    NCT02427802
    Conditions
    Foot Ulcer, Diabetic; Infection
    Interventions
    Gentamicin collagen sponge; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2016-10
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFoot Ulcer, Diabetic; Infection
    InterventionGentamicin collagen sponge; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

    NCT02036528 · start 2014-01

    Registered record
    Registry ID
    NCT02036528
    Conditions
    Diabetic Foot Ulcers
    Interventions
    Gentamicin Topical Gel; Ciprofloxacin; Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2014-01
    Completion
    Not recorded
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Foot Ulcers
    InterventionGentamicin Topical Gel; Ciprofloxacin; Doxycycline
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection

    NCT01951768 · start 2013-09

    Registered record
    Registry ID
    NCT01951768
    Conditions
    Diabetic Foot Ulcer
    Interventions
    Garamycin Sponge (Gentamicin-Collagen sponge); Systemic Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2016-06
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Foot Ulcer
    InterventionGaramycin Sponge (Gentamicin-Collagen sponge); Systemic Antibiotic
    PhasePhase 4
    Registry statusCompleted

  • Gentamicin Bladder Instillation Trial

    NCT01884467 · start 2013-05

    Registered record
    Registry ID
    NCT01884467
    Conditions
    Urinary Tract Infections
    Interventions
    Gentamicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-05
    Completion
    2016-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionGentamicin; Placebo
    PhasePhase 4
    Registry statusUnknown